PGR and breast cancer: Three types of nanoparticles with settled lifetime were conjugated with primary antibodies to label the MCF-7 and BT-474 breast cancer cells, on a basis of detecting the biomarkers of breast cancer including progesterone receptor (PR), oestrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2).